NVUS Novus Therapeutics Inc.

0.64
-0.01  -1%
Previous Close 0.64
Open 0.65
Price To Book 0.62
Market Cap 8,273,162
Shares 12,967,338
Volume 541,402
Short Ratio
Av. Daily Volume 134,240
Stock charts supplied by TradingView

NewsSee all news

  1. Novus Therapeutics Provides Update on OP0201

    – Phase 2a study C-006 enrollment to be completed in 1Q 2020; data expected in 2Q 2020 – Novus Therapeutics, Inc. (NASDAQ:NVUS), a specialty pharmaceutical company focused on developing products for patients with

  2. Novus Therapeutics Announces Exercise of Warrants for $4.7 Million Gross Proceeds

    Novus Therapeutics, Inc. (NASDAQ:NVUS), a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat (ENT), today announced the agreement by several

  3. Novus Therapeutics to Participate in Two Investor Conferences

    Novus Therapeutics, Inc. (NASDAQ:NVUS), a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat (ENT), today announced that the company will participate

  4. Novus Therapeutics Reports Third Quarter 2019 Financial Results

    -- Management to participate in two investor conferences in December 2019 -- -- Data from ongoing phase 2a study C-006 expected in the first half of 2020 -- Novus Therapeutics, Inc. (NASDAQ:NVUS), a specialty

  5. Novus Therapeutics Receives FDA Guidance on OP0201 Phase 2a Study in Patients with Chronic Otitis Media with Effusion

    Novus Therapeutics, Inc. (NASDAQ:NVUS), a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat (ENT), today announced that the U.S. Food and Drug

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 3 trial discontinued July 2016 due to poor data
Galeterone - ARMOR3-SV
Cancer - castration-resistant prostate cancer (CRPC)
Announced in August 2016 that Phase 2 trial enrollment has been discontinued.
Galeterone - ARMOR2
Xtandi (enzalutamide) refractory metastatic castration-resistant prostate cancer (mCRPC)
Phase 1 data presented June 11, 2019, 1pm.
OP0201- C-002
Healthy volunteers
Phase 1 data released April 22, 2019. Safety and tolearbility objectives met.
OP0201 C-001
Healthy volunteers
Phase 1 data released April 22, 2019. Safety and tolerability objectives met.
OP0201
Acute Otitis Media - adults
Phase 2a data due 2Q 2020.
OP0201 - C-006
Acute Otitis Media - children
Phase 1 data released April 22, 2019. Safety and tolerability objectives met.
OP0201 - C-001
Healthy volunteers

Latest News

  1. Novus Therapeutics Provides Update on OP0201

    – Phase 2a study C-006 enrollment to be completed in 1Q 2020; data expected in 2Q 2020 – Novus Therapeutics, Inc. (NASDAQ:NVUS), a specialty pharmaceutical company focused on developing products for patients with

  2. Novus Therapeutics Announces Exercise of Warrants for $4.7 Million Gross Proceeds

    Novus Therapeutics, Inc. (NASDAQ:NVUS), a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat (ENT), today announced the agreement by several

  3. Novus Therapeutics to Participate in Two Investor Conferences

    Novus Therapeutics, Inc. (NASDAQ:NVUS), a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat (ENT), today announced that the company will participate

  4. Novus Therapeutics Reports Third Quarter 2019 Financial Results

    -- Management to participate in two investor conferences in December 2019 -- -- Data from ongoing phase 2a study C-006 expected in the first half of 2020 -- Novus Therapeutics, Inc. (NASDAQ:NVUS), a specialty

  5. Novus Therapeutics Receives FDA Guidance on OP0201 Phase 2a Study in Patients with Chronic Otitis Media with Effusion

    Novus Therapeutics, Inc. (NASDAQ:NVUS), a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat (ENT), today announced that the U.S. Food and Drug

  6. Novus Therapeutics to Participate in Two Upcoming Investor Conferences

    Novus Therapeutics, Inc. (NASDAQ:NVUS), a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat (ENT), today announced that the company will participate